Follow-up of lesions with equivocal radiotracer uptake on PSMA-targeted PET in patients with prostate cancer: predictive values of the PSMA-RADS-3A and PSMA-RADS-3B categories

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
Umfang
Online-Ressource
Sprache
Englisch

Erschienen in
In: Journal of Nuclear Medicine, 60, 4, S. 511-516

Ereignis
Veröffentlichung
(wo)
Augsburg
(wer)
Universität Augsburg
(wann)
2019
Ereignis
Veröffentlichung
(wo)
New York, NY
(wer)
Society of Nuclear Medicine
(wann)
2019
Urheber
Yin, Yafu
Wolf, Herta
Higuchi, Takahiro
Lapa, Constantin Frederik Victor
Pienta, Kenneth J.
Pomper, Martin G.
Gorin, Michael A.
Rowe, Steven P.

DOI
10.2967/jnumed.118.217653
URN
urn:nbn:de:bvb:384-opus4-629859
Rechteinformation
Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
25.03.2025, 13:51 MEZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

Entstanden

  • 2019

Ähnliche Objekte (12)

Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer

Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer

Effect of point-spread function reconstruction for indeterminate PSMA-RADS-3A lesions on PSMA-targeted PET imaging of men with prostate cancer

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging

Unfolding the cardioprotective potential of sigma-1 receptor-directed molecular imaging

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on \(^18}\)F-DCFPyL PET/CT Imaging

Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging

Interobserver agreement for the standardized reporting system PSMA-RADS 1.0 on 18F-DCFPyL PET/CT imaging

A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging

A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging

A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging

A Voice From the Past: Re-Discovering the Virchow Node with PSMA-targeted \(^18}\)F-DCFPyL PET Imaging

Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake

Semiquantitative parameters in PSMA-targeted PET imaging with [18F]DCFPyL: impact of tumor burden on normal organ uptake

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

177Lu-rhPSMA-10.1 induces tumor response in a patient with mCRPC after PSMA-directed radioligand therapy with 177Lu-PSMA-I AND T

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted \(^18}\)F-DCFPyL in peripheral ganglia

Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted \(^18}\)F-DCFPyL in peripheral ganglia

Verbundene Objekte